Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone (vol 11, pg E1743, 2023)

被引：0

|

作者：

不详

机构：

来源：

LANCET GLOBAL HEALTH | 2024年 / 12卷 / 01期

关键词：

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

引用

收藏

页码：E32 / E32

页数：1

相关论文

共 22 条

[21] Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial (vol 16, pg 31, 2016)
Tapia, M. D.
Sow, S. O.
Lyke, K. E.
LANCET INFECTIOUS DISEASES, 2016, 16 (01): : 16 - 16
[22] Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial (vol 22, pg P1703, 2022)
Nsio, J.
Ardiet, D-L
Coulborn, R. M.
LANCET INFECTIOUS DISEASES, 2023, 23 (01): : E1 - E1